– USA, CA – Aether Biomachines, a nanotechnology company building a future of abundance, today announced the appointment of Dr. Erik Scher (Ph.D.) to its Board of Directors.
A distinguished leader with over two decades of experience in the technology industry, Dr. Scher will guide Aether’s team as they develop AI-driven nanotechnology to unlock novel materials, therapeutics, commercial products, and environmental strategies.
“We are thrilled to have Erik join our Board of Directors to support our efforts to push beyond what nature invented and build a new era of products that solve critical real-world problems. Erik’s background in chemistry and engineering will be instrumental to Aether as we work to custom engineer novel, natural proteins into general-purpose molecular assemblers,” said Founder and CEO, Pavle Jeremic.
Dr. Scher joins other Board Directors:
- Austin Che, Co-Founder of Ginkgo Bioworks;
- Shlomo Yanai, former CEO of Teva Pharmaceuticals;
- Stuart Peterson, Managing Partner and Founder at ARTIS Ventures;
- Ameena El-Bibany, Partner at ARTIS Ventures;
- Pavle Jeremic, Aether’s CEO and Founder.
About Dr. Erik Scher
Dr. Scher is an Operating Partner at True North Venture Partners where he works in executive roles at portfolio companies supporting commercialization, strategic planning, and investment decisions. As a founder, board director, technical and commercial leader, and advisory board member for entrepreneurial companies across the energy, chemicals, advanced materials, and consumer product industries, he has helped invent, scale, and commercialize numerous novel technologies. Amongst his operational roles, Dr. Scher served as CCO and President at Hyconix and CEO and COO at Siluria Technologies.
“I am excited to serve on Aether’s Board of Directors and look forward to working with Aether’s leadership team to further develop its one-of-a-kind nanotechnology platform to build a future of abundance,” said Erik Scher. “Aether’s mission and technology have incredible potential to improve global human health and end resource scarcity.”
He received a Ph.D. in Materials Chemistry from the University of California, Berkeley, and a bachelor’s degree in Chemistry from Rice University.
Aether is building the world’s highest throughput robotic factory to custom engineer molecular assemblers that can synthesize new molecules from commonly found chemicals. Recently the company announced a partnership with Allonnia to design enzymes to sustainably remove harmful perfluoroalkyl and polyfluoroalkyl substances from the environment.
About Aether Biomachines
Aether is building a future of abundance for humankind in a post-scarcity world. Powered by one of the world’s highest throughput robotic protein expression and screening laboratories, the company is generating data on scales previously not possible to feed deep AI algorithms. Aether’s platform uses nanotechnology to custom engineer novel, natural proteins into general-purpose molecular assemblers that can synthesize new molecules from commonly found chemicals, unlocking materials, therapeutics, products, and environmental strategies previously unimaginable.
For more information: https://www.aetherbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
